AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk 
DaVoice Sues Perplexity AI Over Trade Secrets 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Trump Signs Order to Cut Routine Childhood Vaccines 
Add as a preferred source on Google
Drugmaker Merck has partnered with Daiichi Sankyo, under which it will pay $5.5 billion to develop three candidate cancer drugs jointly. This deal could be worth up to $22 billion for Daiichi Sankyo, depending on the success of the therapies.
Shares of Daiichi Sankyo soared by 14.4% in Tokyo, marking their largest gain in over a year. Merck also saw a rise of 1.6% in morning trading.
Ambitious Revenue Target for Daiichi Sankyo's Oncology Business
According to Reuters, Daiichi Sankyo has set a revenue target of at least 900 billion yen ($6 billion) for its oncology business by the fiscal year ending March 31, 2026. This would represent an impressive five-fold increase over three years.
Investopedia noted that the three-drug candidates to be developed with Merck fall into the antibody-drug conjugates (ADC) class, with various stages of clinical development for treating multiple solid cancer tumors. Unlike conventional chemotherapy, ADCs are designed to target cancer cells, minimizing damage to healthy cells specifically.
"One of the changes in the external environment is intensifying competition in ADC development," Daiichi Sankyo CEO Sunao Manabe said, describing the company's decision to seek a partner.
Promising Commercial Revenue Potential
The drug candidates - patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan - hold significant worldwide commercial revenue potential for both companies by the mid-2030s, according to Merck and Daiichi Sankyo.
Under the agreement, Merck and Daiichi Sankyo will jointly develop and potentially commercialize the drug candidates globally, except in Japan, where Daiichi Sankyo will retain exclusive rights. Daiichi Sankyo will be responsible for manufacturing and supply.
Merck Gains Access to Daiichi Sankyo's Expertise in the ADC Space
The partnership allows Merck to tap into Daiichi Sankyo's leadership status in the ADC field. Analysts believe this collaboration will strengthen Merck's cancer drug portfolio, particularly as its top-selling Keytruda faces patent expiration at the end of the decade.
In return for the collaboration, Merck will make an upfront payment of $4 billion to Daiichi Sankyo, followed by $1.5 billion in continuation payments over the next two years. Additionally, Merck may pay up to $16.5 billion based on future sales milestones, amounting to $5.5 billion for each product.
Daiichi Sankyo has six ADC candidates in its pipeline, including two jointly developed with AstraZeneca. However, this week's disappointing data abstract on the late-stage trial of datopotamab deruxtecan, developed with AstraZeneca, has impacted analysts' expectations.
Photo: Merck Media
